Table S1. Clinical characteristics in patients with ROS1-positive.

Case	Gender/age (years)	Histology subtype	Fusion subtype	Crizotinib treatment	PFS/months
1	M/62	Papillary pred	EZR	–	–
2	F/47	Lepidic pred	CD74	–	–
3	M/45	Papillary pred	GOPC	Yes	6.0
4	F/45	NA	CD74	Yes	15.5
5	F/43	Papillary pred	EZR	–	–
6	M/46	Solid pred	CD74	–	–
7	M/59	Papillary pred	SDC4	–	–
8	F/60	Micropapillary pred	SLC34A2	Yes	18.0+
9	M/49	Micropapillary pred	SDC4	–	–
10	F/72	Minimally invasive	SLC34A2	–	–
11	M/65	Papillary pred	CD74	–	–
12	F/47	NA	SDC4	–	–
13	M/56	Micropapillary pred	EZR	Yes	14.2+
14	F/66	Acinar pred	CD74	–	–
15	F/44	Micropapillary pred	CD74	Yes	15.0+
16	F/67	Acinar pred	CD74	–	–
17	M/69	Papillary pred	TPM3	–	–
18	F/70	Micropapillary pred	EZR	Yes	9.5+
19	F/45	Solid pred	CD74	–	–
20	F/69	Solid pred	GOPC	–	–
21	F/61	Solid pred	GOPC	–	–
22	M/61	NA	SDC4	–	–
23	M/49	Lepidic pred	CD74	–	–
24	M/48	Papillary pred	SDC4	–	–
25	F/47	Solid pred	GOPC	–	–
26	F/51	Papillary pred	CD74	–	–
27	F/51	Solid pred	CD74	–	–
28	M/47	NA	CD74	–	–
29	M/57	Acinar pred	LRIG3	–	–
30	M/65	Solid pred	TPM3	–	–
31	M/60	Lepidic pred	GOPC	–	–
32	F/39	Solid pred	LRIG3	–	–

Pred, predominant; NA, not applicable; PFS, progression-free survival; ROS1, c-ros oncogene 1.